Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

(2021) Juan P Frías et al.   Lancet Diabetes & Endocrinology

GLP-1 receptor agonists: which added value when increasing the dose?

(2021) André J Scheen   Lancet Diabetes & Endocrinology

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

(2020) Ricardo J. Samms et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

(2020) Francis S. Willard et al.   JCI Insight

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

(2020) Laurie L. Baggio et al.   Molecular Metabolism

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

(2020) Melissa K Thomas et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

(2020) Thinzar Min et al.   Diabetes Therapy

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

(2019) V. R Aroda et al.   DIABETES & METABOLISM

The liver-alpha cell axis and type 2 diabetes

(2019) Nicolai J Wewer Albrechtsen et al.   ENDOCRINE REVIEWS

Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide

(2019) Vivian A Fonseca et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy

(2019) Jens Juul Holst   Frontiers in Endocrinology

Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes

(2019)   DIABETES CARE

Incretin hormones: Their role in health and disease

(2018) Michael A. Nauck et al.   DIABETES OBESITY & METABOLISM

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function

(2017) Sudip Bajpeyi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Reappraisal of GIP Pharmacology for Metabolic Diseases

(2016) Brian Finan et al.   TRENDS IN MOLECULAR MEDICINE

Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass

(2014) Dariush Elahi et al.   Surgery for Obesity and Related Diseases

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes

(2013) Mikkel B. Christensen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE